Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
27,202,736
-
Share change
-
+16,626
-
Total reported value
-
$474,936,380
-
Put/Call ratio
-
183%
-
Price per share
-
$17.46
-
Number of holders
-
83
-
Value change
-
-$25,989,904
-
Number of buys
-
47
-
Number of sells
-
43
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2016
As of 31 Mar 2016,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
83 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,202,736 shares.
The largest 10 holders included
Essex Woodlands Health Ventures, Inc., FRANKLIN RESOURCES INC, NQ HCIF GP, Ltd., JPMORGAN CHASE & CO, Bank of New York Mellon Corp, WELLINGTON MANAGEMENT GROUP LLP, Polar Capital LLP, BlackRock Fund Advisors, Arrowpoint Asset Management, LLC, and VANGUARD GROUP INC.
This page lists
83
institutional shareholders reporting positions in this security
for the Q1 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.